Categories
Credit Cards

Merrill Lynch Stick to Their Buy Rating for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, and that is roughly 9.11 % above the existing share price of $76.07.

Cherny expects CVS Health Corp to post earnings per share (EPS) of $0.93 for the first quarter of 2021.

The present opinion among 11 TipRanks analysts is for a reasonable Buy rating of shares in CVS Health, with an average price target of $84.

The analysts price targets range from a high of hundred one dolars to a low of $61.

From its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net benefit of $3.25 billion. The company’s market cap is actually $99.57 billion.

Based on TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with four stars on a 0-5 stars ranking scale, with an average return of 11.5 % and a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment extends pharmacy benefit management strategies. The Long or retail Term Care segment has selling of prescription medications and assortment of general merchandise.

The Health Care Benefits segment offers traditional, consumer-directed and voluntary health insurance products and similar services, including medical, pharmacy, dental, behavioural health, medical relief capabilities. The Corporate segment involves in offering administrative services and management. The company was developed by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.

Leave a Reply

Your email address will not be published. Required fields are marked *